Eisai Co., Ltd (ESALY) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Eisai Co., Ltd (NASDAQ:ESALY) from a buy rating to a sell rating in a research note published on Tuesday morning.

According to Zacks, “Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products. Operations are carried out through the following divisions: Pharmaceuticals: veterinary drugs other food additives, livestock feed and pharmaceutical production systems and equipment. The Group has overseas consolidated subsidiaries in the United States, Canada, the United Kingdom, France, Germany, East Southeast Asia and South and Central America. “

Eisai Co. (NASDAQ:ESALY) opened at 63.92 on Tuesday. Eisai Co. has a 52 week low of $53.55 and a 52 week high of $67.60. The firm’s 50-day moving average price is $61.72 and its 200 day moving average price is $60.45. The company has a market capitalization of $18.28 billion and a PE ratio of 26.95.

5 Day Chart for NASDAQ:ESALY

Get a free copy of the Zacks research report on Eisai Co. (ESALY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eisai Co. Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai Co. Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.